Treatment and management of myelofibrosis in the era of JAK inhibitors by Keohane C, Radia DH, Harrison CN

Get full text

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum] by Keohane C, Radia DH, Harrison CN

Get full text

CNL and aCML should be considered as single entity based on molecular profiles and outcomes by Carreño-Tarragona, G, Alvarez-Larran, A, Harrison, CN, Martínez-Ávila, JC, Hernandez-Boluda, JC, Ferrer-Marin, F, Radia, DH, Mora Casterá, E, Francis, S, González-Martínez, T, Goddard, K, Perez-Encinas, M, Narayanan, S, Raya, JM, Singh, V, Toth, P, Gutiérrez, X, Amat Martinez, P, McIlwaine, L, Alobaidi, M, Mayani, K, McGregor, A, Stuckey, R, Psaila, B, Segura, A, Alvares, CL, Davidson, K, Osorio, S, Cutting, R, Sweeney, CP, Rufian, L, Moreno, L, Cuenca, I, Smith, J, Morales, ML, Gil-Manso, R, Koutsavlis, I, Wang, L, Mead, AJ, Rozman, M, Martínez-López, J, Ayala, R, Cross, NC